Human Tubal-Derived Mesenchymal Stromal Cells Associated with Low Level Laser Therapy Significantly Reduces Cigarette Smoke-Induced COPD in C57BL/6 mice

Author(s):Show less -

Schatzmann Peron, Jean Pierre ^[1] ; de Brito, Aurileia Aparecida ^[2] ; Pelatti, Mayra ^[3] ; Brandao, Wesley Nogueira ^[1] ; Vitoretti, Luana Beatriz ^[2] ; Greiffo, Flavia Regina ^[2] ; da Silveira, Elaine Cristina ^[2] ; Oliveira-Junior, Manuel Carneiro ^[3] ; Maluf, Mariangela ^[4] ; Evangelista, Lucila ^[5] ; Halpern, Silvio ^[5] ; Nisenbaum, Marcelo Gil ^[5] ; Perin, Paulo ^[4] ; Czeresnia, Carlos Eduardo ^[5] ; Saraiva Camara, Niels Olsen ^[6] ; Aimbire, Flavio ^[7] ; Vieira, Rodolfo de Paula ^[3] ; Zatz, Mayana ^[2] ; Ligeiro de Oliveira, Ana Paula ^[3]

Affiliation

^[1] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Neuroimmune Interact Lab, Sao Paulo, SP - Brazil

^[2] Nove Julho Univ UNINOVE, Lab Pulm & Exercise Immunol LABPEI, Sao Paulo, SP - Brazil

^[3] Univ Sao Paulo, Div Human Genome, Res Ctr, Biosci Inst, Sao Paulo, SP - Brazil

^[4] CEERH Specialized Ctr Human Reprod, Div Reprod Med, Sao Paulo, SP - Brazil

^[5] Div Reprod Med Celula Mater, Sao Paulo, SP - Brazil

^[6] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Lab Transplantat Immunobiol, Sao Paulo, SP - Brazil

^[7] Univ Fed Sao Paulo, Dept Sci & Technol, Sao Jose Dos Campos, SP - Brazil

• Document type: Journal article
• Source: PLoS One; v. 10, n. 8 AUG 31 2015.
• Web of Science Citations: 13

Abstract

Cigarette smoke-induced chronic obstructive pulmonary disease is a very debilitating disease, with a very high prevalence worldwide, which results in a expressive economic and social burden. Therefore, new therapeutic approaches to treat these patients are of unquestionable relevance. The use of mesenchymal stromal cells (MSCs) is an innovative and yet accessible approach for pulmonary acute and chronic diseases, mainly due to its important immunoregulatory, anti-fibrogenic, anti-apoptotic and pro-angiogenic. Besides, the use of adjuvant therapies, whose aim is to boost or synergize with their function should be tested. Low level laser (LLL) therapy is a relatively new and promising approach, with very low cost, no invasiveness and no side effects. Here, we aimed to study the effectiveness of human tube derived MSCs (htMSCs) cell therapy associated with a 30mW/3J-660 nm LLL irradiation in experimental cigarette smoke-induced chronic obstructive pulmonary disease. Thus, C57BL/6 mice were exposed to cigarette smoke for 75 days (twice a day) and all experiments were performed on day 76. Experimental groups receive htMSCS either intraperitoneally or intranasally and/or LLL irradiation either alone or in association. We show that co-therapy greatly reduces lung inflammation, lowering the cellular infiltrate and pro-inflammatory cytokine secretion (IL-1 beta, IL-6, TNF-alpha and KC), which were followed by decreased mucus production, collagen accumulation and tissue damage. These findings seemed to be secondary to the reduction of both NF-kappa B and NF-AT activation in lung tissues with a concomitant increase in IL-10. In summary, our data suggests that the concomitant use of MSCs + LLLT may be a promising therapeutic approach for lung inflammatory diseases as COPD. (AU)

• FAPESP's process: 12/16498-5 - Effect of low level laser therapy in experimental models of pulmonary chronic diseases
• Grantee: Ana Paula Ligeiro de Oliveira
• Support Opportunities: Research Grants - Young Investigators Grants
• FAPESP's process: 11/18703-2 - The role of Indoleamine-2,3-dioxigenase and the Triptophan - Kynurenines axis through NMDA receptors over the immune response in the EAE and stroke model
• Grantee: Jean Pierre Schatzmann Peron
• Support Opportunities: Research Grants - Young Investigators Grants